We found that in lung adenocarcinoma, compared with NOTCH4-WT patients (ORR = 21.2%), NOTCH4-MUT patients (ORR = 25.0%) tended to have a better response to ICI treatment (Additional file 3: Figure S2A). This evidence concerns the gene NOTCH4 and lung adenocarcinoma.